CureGenetics

The company's primary business involves creating treatments for hard-to-treat solid tumors and complex genetic diseases. It operates through a business model that combines in-house research and development with strategic collaborations and out-licensing agreements. A notable partnership includes a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectors for liver-targeted gene therapy. Another significant agreement with Frametact Limited, valued at up to $60 million, focuses on developing AAV vectors for familial neurological diseases. Revenue is generated through upfront payments, milestone achievements, and future sales royalties from these collaborations.

CureGenetics has developed two proprietary technology platforms: AIMS™ CAR-NKT for cell therapy and VELP™ for AAV discovery. The AIMS™ CAR-NKT platform is engineered to enhance the infiltration of immune cells into solid tumors. Its lead candidate from this platform, CGC729, has shown a good safety profile and anti-tumor activity in clinical trials for renal cell carcinoma. The VELP™ (Vector Engineering Library Production) platform is designed for the high-throughput screening of AAV capsids to identify new vectors with better tissue specificity and safety profiles, addressing the limitations of existing AAV serotypes. The company also utilizes an optimized CRISPR-Cas9 gene editing platform for developing its cell-based therapies.

Since its inception, CureGenetics has secured significant funding to advance its research and clinical pipelines. The company raised a $2.2 million angel round in 2017, a $17 million Series A in 2018, a $12.5 million Series A+ in 2020, and a $60 million Series B in 2022, with investors including Qiming Venture Partners and Advantech Capital. These funds support the optimization of its technology platforms, investigational new drug (IND) applications, and clinical trials. The company operates from a research center in Suzhou Industrial Park and is constructing a larger development facility. Keywords: gene therapy, cell therapy, CRISPR-Cas9, AAV vectors, CAR-NKT, oncology, genetic diseases, solid tumors, viral delivery systems, molecular diagnostics, drug discovery, biotechnology, Suzhou, China, Yuanyuan Xu, Yanni Lin, Boehringer Ingelheim collaboration, Frametact collaboration, Qiming Venture Partners, Advantech Capital, AIMS CAR-NKT, VELP platform, renal cell carcinoma, neurological diseases, gene editing therapeutics